February 2022 Trevena Announces Submission of New Drug Application in China for OLINVYK® by its Partner Jiangsu The NDA was submitted by Trevena’s partner, Jiangsu Nhwa Pharmaceutical, and follows completion by Nhwa

Ji, et al. 2020; L. Wan, 2020). Ji et al., 2020).

Jianming Han , Tao Che  for their analysis of GPCR-G protein selectivity revealed by structural pharmacology

Jiang, L.I., et al., Use of a cAMP BRET sensor to characterize a novel regulation of cAMP by the sphingosine

guide to heterotrimeric G protein activity biosensors Marta Lopez-Balastegui , Antonella Di Pizio , Jiafei

extracellular CUB domain of the adhesion GPCR ADGRG6/GPR126 is a key regulator of receptor signaling Jiankun

for their investigation on Molecular insights into G protein coupling specificity at a class A GPCR Jianjun

and disease GPCR Binders, Drugs, and more Elucidation of active components and target mechanism in Jinqiancao

References: Jin, B. K., Odongo, S., Radwanska, M., & Magez, S. (2023).